

URGENT DRUG PRODUCT RECALL

June 24, 2025

Dear Customer,

This is to inform you that Granules Pharmaceuticals Inc. is voluntarily recalling below product:

Drug Product Name	Metoprolol Succinate Extended-Release Tablets USP, 25 mg
ANDA / NDA Number	216916
Firm Drug Product Code	140
Dosage Form	Tablets
Lot Numbers	1400008A and 1400008B
Intended Use/ Indications	Metoprolol Succinate Extended-Release Tablets USP, 25 mg is a beta-blocker used to treat chest pain (angina), heart failure, and high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems.
Description of Product	White to off white, oval shaped, film coated scored tablets, debossed with "I" and "25" on either side of score line on one side and score line on other side. Free from physical defects
Package Type and Sizes/Number of Doses	100 and 500 counts in HDPE bottle
NDC Number	70010-780-01 and 70010-780-05

The recall is initiated due to Metoprolol Succinate ER Tablets 25mg, batch number #1400008A (100-count), failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25°C/60% RH) long-term. Consequently, batch number #1400008B (500-count), also manufactured from the same bulk batch #1400008. No adverse events have been received to-date for the above-mentioned product lot.

Shipping date, Quantity, Manufacturing date and Expiry date of the impacted product lot are as follows:

Batch Number	First Ship Date	Last Ship Date	Shipped Quantity	Mfg. Date	Exp. Date
1400008A	07/18/2024	11/18/2024	27648 Bottles	01/2024	2025/12
1400008B	07/26/2024	08/05/2024	5376 Bottles	01/2024	2025/12

Immediately examine your inventory and quarantine product subject to recall. In addition, if you may have further distributed this product, please identify your customers, and notify them of this product recall. Your notification to your customers may be enhanced by including a copy of this recall notification letter.

We request you to collect the entire recalled product and provide reconciliation of the product received. Kindly request a Qualanex (Inmar) LLC, Return Authorization by emailing Qualanex@recall.com. The returned recall product should be returned to Qualanex (Inmar) LLC, 1410, Harris Rd, Libertyville, IL – 60048 by using the

3701 & 3725 Concorde Parkway Chantilly, VA 20151 Phone No. 571-325-5950 Fax No.703-378-1578

1 dx 140.700 070 1070

Return Authorization Notification Form. Provide the recalled product details by completing the enclosed recall response form.

This recall should be carried out to the retail level.

Included below are the labels associated with the recalled product.



Your assistance is appreciated and necessary to prevent consumer illness or patient harm.

Please complete and return the enclosed response form and email it to <u>sandeep.uppaluri@granulesindia.com</u> or fax at 703-378-1578. If you have any questions, please contact with the below mentioned communication details,

Sandeep Uppaluri

Tel: 571-752-6816, Email: Sandeep.uppaluri@granulesindia.com

For Adverse Event (ADE) Reporting, please contact 877-770-3183

This recall is being made with the knowledge of the Food and Drug Administration.

Rajesh Kapoor Digitally signed by Rajesh Kapoor Date: 2025.06.24 08.19.23 -04'00'

Rajesh Kapoor Global Quality Head, Granules



3701 & 3725 Concorde Parkway Chantilly, VA 20151 Phone No. 571-325-5950 Fax No.703-378-1578

Recall Return Response Form

June 24, 2025

Drug Product Name	Metoprolol Succinate Extended-Release Tablets USP, 25 mg
Lot Numbers	1400008A and 1400008B
Expiry Date	December, 2025
Description of Product	White to off white, oval shaped, film coated scored tablets, debossed with "I" and "25" on either side of score line on one side and score line on other side. Free from physical defects
Package Type and Sizes/Number of Doses	100 and 500 counts in HDPE bottle
NDC Number	70010-780-01 and 70010-780-05

Please check ALL ap	propriate l	boxes.
---------------------	-------------	--------

Please complete this form and fax it back to 1-703-378-1578 or email to Sandeep.uppaluri@granulesindia.com

□ I have read and understand the recall instructions provided in the June 24, 2025 letter.	
☐ I have checked my stock and have quarantined inventory consisting of above lot numbers.	

□ Quantity Held for return (specify quantity in the below table)

Lot Number	Quantity on Hand
1400008A	
1400008B	

□ I have identified and notified my custom shipped this product by (specify date and	ners that were shipped or may have been method of notification):
Facility/Distribution Center Name:	
Address:	
Personnel Name:	
Title:	
Email ID:	
Tel. number:	
Signature:	Date: